

ABSTRACT

Background: Kounis syndrome (KS) is defined as a rare cause of an acute coronary syndrome associated with systemic allergic reactions.

Objectives: To establish the prevalence of KS among the patients with diagnosis of anaphylaxis and describe clinical features, cardiological and allergological outcomes of patients evaluated in our Allergy Outpatient Clinic.

Methods: A retrospective study was carried out in the Allergy Unit of Novara hospital, from January 2008 to March 2020. Skin tests and in vitro tests were performed with suspected etiological agents.

Results: We found 9 adults with KS (2%) out of 444 subjects who had experienced anaphylactic reactions (4/9 to hymenoptera stings, 5/9 to drugs).

Conclusions: The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.

ABBREVIATIONS

ACLS: advanced cardiac life support

AX/clav: amoxicillin + clavulanic acid

BAT: basophil activation test

ECG: electrocardiogram

ED: emergency department

ICM: iodinated contrast media

ICU: intensive care unit

IDT: intradermal test

KS: Kounis syndrome

PEA: pulseless electrical activity

PoD: Polistes dominula

sBT: serum basal tryptase

sIgE: serum specific IgE

SPT: skin prick test

STs: skin tests

STEMI: ST-elevated myocardial infarction

VIT: venom immunotherapy

YJ: yellow jacket

KEY WORDS: Kounis syndrome, anaphylaxis, coronary vasospasm, hypersensitivity, drugs, hymenoptera.

AN IMPACT STATEMENT: This report has a relatively large number of patients diagnosed with Kounis Syndrome from one center with potential messages about triggers and an allergy work-up.

INTRODUCTION

Kounis syndrome (KS) is a hypersensitivity coronary disorder of which three types have been characterized.^{1,2} The type I variant refers to the syndrome in patients with no history of coronary artery disease experiencing coronary vasospasm with or without progression to myocardial infarction in response to an allergic reaction. The type II KS includes patients with preexisting atheromatous disease in whom an allergic reaction can induce either coronary artery spasm with normal cardiac biomarkers and troponin levels or coronary artery spasm together with plaque erosion or rupture manifesting as acute myocardial infarction. The type III KS includes patients in whom stent thrombosis (subtype a) or stent restenosis (subtype b) occurs in response to an allergic reaction.

KS is caused by inflammatory mediators, such as histamine, platelet-activating factor, and eicosanoids, which are released during the allergic reaction. Most of these mediators have important cardiovascular actions and during anaphylaxis they contribute to vasoconstriction and coronary artery spasm. Mast cells are present in cardiac tissue, including coronary arteries, and their density is increased in patients with coronary heart disease.^{1,3-5} This implies that heart and especially coronary arteries can constitute primary targets in anaphylaxis⁶ so that acute ischemic events, including angina and myocardial infarction, are considered currently as part of the clinical picture of anaphylaxis.³ Kounis-like syndromes can also affect mesenteric⁷ and cerebral arteries.⁸⁻¹⁰

Patients with systemic allergic reactions associated with clinical, electrocardiographic, angiographic, echocardiographic, and laboratory (i.e., increase in cardiac enzyme and troponin levels) findings of acute myocardial ischemia should be diagnosed as having KS.² Allergic symptoms, compatible history, increase in serum tryptase levels, positive skin tests (STs), and/or positive serum specific IgE (sIgE) assays constitute the basis for diagnosing an allergic reaction. The KS triggers reported most frequently are drugs, foods, environmental exposures (e.g., hymenoptera stings, insect bites, and latex contact), and clinical conditions (e.g., anisakiasis, idiopathic anaphylaxis, mastocytosis, and intracoronary stenting).^{1,2} Almost all of the works in the literature are the report either of single cases

or of a very small number of patients, mainly in adults.^{11,12} In this study, we describe a series of nine KS patients, six of whom underwent complete allergy work-up which included STs and in vitro tests.

MATERIALS AND METHODS

Patients

A retrospective study was carried out in the Allergy Unit of Novara hospital (northwest Italy), from January 01, 2008 to March 05, 2020.

During this period, out of 24,535 patients seen for allergic diseases, 444 were diagnosed with anaphylaxis and 9 of these were diagnosed with KS. Anaphylactic reactions were diagnosed according to the clinical criteria proposed by Sampson et al.¹³ The severity of reactions was graded according to Ring and Messmer.¹⁴

All patients signed an informed consent for the diagnostic procedure.

Since the study was strictly retrospective, based on routine clinical practice, no approval by ethical review board was required.

In vivo tests

Skin testing

Patients who had experienced hypersensitivity reactions to hymenoptera stings underwent STs with hymenoptera venoms according to international guidelines.¹⁵⁻¹⁷

Patients who reported hypersensitivity reactions to drugs (beta-lactams and iodinated contrast media) underwent a standardized allergy work-up according to the EAACI drug allergy interest group guidelines.¹⁸⁻²¹

In vitro tests

Serum tryptase assay

Serum basal tryptase (sBT) was measured with an immunofluorimetric assay (ImmunoCAP Thermofisher Scientific, Uppsala, Sweden) during an asymptomatic period. The cutoff value of tryptase was considered to be ≥ 11.4 $\mu\text{g/L}$ in accordance with the manufacturer's instructions. In subjects in whom tryptase assay was performed within 2-4 hours of reaction, values above 120% of

the baseline value + 2 (baseline value x 1.2 + 2) were considered significant for an anaphylactic event.²²

Serum specific IgE assay

We performed assays for serum specific IgE (sIgE) to penicilloyl G, penicilloyl V, ampicilloyl, amoxicilloyl, and cefaclor with ImmunoCAP (Phadia, Uppsala, Sweden, now Thermo Fisher Scientific) in all subjects with reactions to β -lactams. Subjects who had reacted to hymenoptera stings underwent assays for sIgE to their venoms. A value of 0.35 kUA/L or greater was considered positive.

Basophil activation test

A basophil activation test (BAT) was performed for drugs for which no alternative in vitro tests were available and if the symptoms in the patient history suggested that skin testing could provoke systemic reactions.²³ The BAT was carried out at the immunology laboratory of IRCCS of Pavia with the responsible drug and alternative ones for evaluating patterns of cross-reactivity, using CD63 as activation marker. A result with CD63 >5% and Stimulation Index > 2 was considered significant.²⁴

RESULTS

Tables I and II show the demographics, clinical features, cardiological and allergological outcomes of the 4 subjects who had reacted to hymenoptera stings (2 patients had type I KS and 2 patients had type II KS) and of the 5 individuals with anaphylactic reactions to drugs (4 patients had type I KS and 1 patient had type II KS), respectively.

In the first four subjects (Table I), an IgE-mediated hypersensitivity to the responsible hymenoptera venom was diagnosed.

The first subject had experienced severe anaphylaxis in July 2016 after being stung in his garden by three *Polistes dominula* (PoD), despite having immunotherapy with 100 μ g of PoD venom every 8 weeks and being given a dose of intramuscular self-injectable epinephrine. In the previous reaction of 2010, he had had desaturation and loss of consciousness after a PoD sting. In that occasion, a slight increase in troponin value was found and doubtful alterations in repolarization were noted on the electrocardiogram (ECG); a coronarography was excluded for negativity of ergometric test. On the

occasion of the second reaction, a coronarography evidenced a multivessel artery disease for which the patient underwent coronary artery bypass graft surgery. Therefore, a diagnosis of type-I KS is likely for the first reaction and type II for the second reaction.

After three months an allergy workup confirmed a mono-sensitization to PoD venom; therefore, PoD VIT was continued at the dose of 200 µg.

Patient 2 had suffered an anaphylactic reaction after a vespid sting in June 2018. He was admitted to the emergency department (ED) where he was immediately treated with intravenous glucocorticoid and intramuscular epinephrine. The ECG showed a diffuse anterior ST-elevated myocardial infarction (STEMI, Figure 1). He underwent percutaneous transluminal coronary angioplasty for critical single-vessel coronaropathy (stenosis in the interventricular anterior coronary artery). Four months later, an IgE-mediated hypersensitivity to yellow jacket (YJ) venom was diagnosed and the related VIT was prescribed.

Patient 3 had experienced moderate anaphylaxis after a vespid sting in September 2008. Two months later we diagnosed IgE-mediated hypersensitivity to YJ venom and prescribed the VIT concerned.

Patient 4 had had severe anaphylaxis after vespid sting in March 2014. Multiple sensitizations to hymenoptera venoms were found two months later at the allergy evaluation. Since the patient and his wife reliably identified YJ as stinging insect, we prescribed immunotherapy for its venom.

Regarding individuals reporting reactions to drugs (Table II), patient 5, who had experienced a severe anaphylaxis after administration of an unknown iodinated contrast media (ICM) in July 2014, was evaluated in our center 5 years later for suspected food allergy.

Patient 6 had suffered severe anaphylaxis few minutes after the assumption of the first tablet of amoxicillin + clavulanic acid (AX/clav) for treatment of pharyngitis in February 2016. One month later she was referred to our center and she reported conjunctival hyperemia and eyelid angioedema a few months earlier while she was giving a syrup of amoxicillin to her grandson. An IgE-mediated hypersensitivity to aminopenicillins and other β-lactams was diagnosed on the basis of positive responses to STs.

Patient 7 was hospitalized in June 2018 for a community-acquired pneumonia, which was treated with intravenous ceftriaxone that she had tolerated six months earlier. Ten minutes after the first dose (2 g), she had experienced severe anaphylaxis. One month later she was referred to our allergological center. In relation to the severity of the reaction, in a history clearly suggestive for IgE mediated allergy, STs were not performed, nevertheless negativity of measurement of sIgE for beta-lactams antibiotics.

Patient 8 had had severe anaphylaxis few minutes after the first dose of AX/clav orally in January 2019. One month later she underwent allergy work-up, displaying positive results to penicillins sIgE.

Patient 9 was hospitalized in a cardiology unit for a STEMI in January 2020. During percutaneous transluminal coronary angioplasty, that showed a critical single-vessel disease, she developed a severe allergic reaction to ioversol with coronary spasm (Figure 2) and a peri-arrest condition. She was immediately treated with intravenous glucocorticoid and intracoronary epinephrine at dose of 0.1 mg which induced an initial resumption of the circle, followed by a ventricular tachycardia and hypotension which required treatment with cardiac electroshock, amiodarone, and noradrenaline.

Six months later, she underwent BAT with iomeprol, iobitridol, iopamidol, iohexol, iopromide, and ioversol, presenting positive responses to four ICM, including the responsible one. STs with iopromide were performed (SPT at 370 mg/ml; IDT at 37 mg/ml) with negative results.

DISCUSSION

In our study the overall prevalence of KS among the patients with diagnosis of anaphylaxis was 2% (9 of 444 subjects). KS diagnosis was made in only 2 cases at the discharge from ED (by a cardiologist) and from Internal Medicine Unit (by an allergist, with subsequent reporting of adverse reaction to the pharmacovigilance system), respectively. In the other cases, the diagnosis was made retrospectively in the allergy unit based mainly on the clinical manifestations, ECG, and laboratory examinations. Cardiovascular involvement (chest pain, hypotension, loss of consciousness, cardiac arrest) was described in 8 patients, respiratory symptoms (dyspnea, bronchospasm, desaturation, cyanosis) in 7, muco-cutaneous manifestations (itching, erythema, urticaria, angioedema) in 6; throat

tightness in 5, gastrointestinal symptoms (vomiting, abdominal pain) in 2, and urinary incontinence in one. Two patients had reactions of grade III and 5 patients had reactions of grade IV. The grades III and IV of the Ring and Messmer system may correlate with KS symptomatology.²

In all four patients with PEA the recovery was complete without cerebral or neurological sequelae.

In three patients cardiological alterations were found (Kounis type II), while the other six patients had normal coronary arteries (Kounis type I).

A variety of electrocardiographic changes ranging from ST segment elevation or depression to any degree of heart block and cardiac arrhythmias can be observed in KS.¹

Vasospasm of the coronary arteries has been suggested to be the main pathophysiologic mechanism.

Images from coronarography of patient 9 may confirm this hypothesis (figure 2).

Anaphylactic reaction presenting as acute angina or myocardial infarction are being reported increasingly.³

There are several observations of myocardial infarction and severe arrhythmia following intravenous epinephrine injections, but in our study only two patients had received epinephrine intramuscularly in the outside of the thigh (patient 1 used an epinephrine autoinjector and patient 2 was treated at the admission to the ED) and in this way the risk of cardiac side effects is minimized.³ However, myocardial infarction after therapeutic doses of intramuscular epinephrine has been rarely reported.^{25,26}

In 8 out of 9 patients, basal serum tryptase levels were determined with normal result ($< 11.4 \mu\text{g/L}$), while tryptase measurement in acute phase was performed only for patients 2 and 7, with positive results.

Regarding etiologic agents, in our series, drugs (i.e., β -lactams and ICM) and hymenoptera stings were responsible for KS. In two patients, KS was caused by the same agent responsible for a previous reaction (PoD in patient 1 and amoxicillin in patient 6).

Our findings are consistent with observation that drugs, especially antibiotics, represent the most common cause of KS.^{27,28} Two reviews^{29,30} analyzed 17 case reports of patients with KS due to β -

lactams (aminopenicillins in 10 out of 17 patients) and 15 of patients with KS related to amoxicillin or AX/clav, respectively. The review by Ridella²⁹ identified middle-aged man as the typical patient with KS, while in our case series patients presenting with KS secondary to drugs were all of female gender and patients with hymenoptera allergy were all males.

Literature also provides description of case reports of KS associated with ICM^{1,2,31-45} and with hymenoptera stings.⁴⁶⁻⁵⁴

Note that only few subjects with KS related to drugs and hymenoptera stings underwent allergy tests, particularly STs, and presented positive results to the culprit drugs, specifically, amoxicillin,⁵⁵⁻⁵⁸ ceftriaxone,⁵⁹ cefazolin,⁶⁰⁻⁶⁴ cefuroxime,⁶⁵ ICM^{37,44} or to hymenoptera venoms.^{49,54}

In patients with drug allergy and PEA we didn't perform STs thinking that in this type of patients at higher risk skin testing may result in systemic response.¹⁸

In fact, a case of KS after IDT with amoxicillin was reported, even if the concentrations used for STs were not specified.⁶⁶ Other systemic reactions after STs in patients with KS related to amoxicillin administration were described after SPT with a high-diluted concentration of amoxicillin (0.1 mg/ml)⁵⁵ and after ID with 20 mg/ml amoxicillin.⁵⁶ Only for patient 9, on the base of risk-benefit analysis for a future risk for other ischemic heart diseases, we performed STs with iopromide, after a negative result at BAT.

Regarding our patients with KS related to hymenoptera stings, a complete diagnostic work-up (i.e., sIgE assays and STs) was performed in all four patients, nevertheless reactions severity, with positive results. REMA score was negative (< 2) for all the patients. VIT was therefore initiated which was well tolerated.

An incomplete allergy diagnostic work-up can be considered as a limit of this study, mainly for hypersensitivity reactions to drugs, justified by severity and rarity of this syndrome. Because of KS reactions' severity, performing in vitro tests before STs may reduce the need for the latter, lessening the risk of systemic reactions.^{18,23,67}

CONCLUSIONS

In conclusion, the present case series highlights the importance of suspicion and early recognition of this syndrome that appears rare in general population but not so uncommon in patients with diagnosis of anaphylaxis, which in our study was 2%. It is advisable to refer subjects who experienced KS to allergy centers in order to undergo diagnostic work-up, even if at present time data regarding a complete allergy diagnostic work-up are lacking.

CONFLICT OF INTERESTS

The authors declare that they have no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank Dr. P. Pignatti, MD of Allergy Unit, Istituti Clinici Scientifici Maugeri of Pavia, for BAT.

FUNDING: The authors declare that no funding was received for the present study

FIGURE LEGENDS

Figure 1. ECG of patient N 2 at the emergency department: sinus rhythm, 95 bpm, antero-lateral ST segment elevation and Q waves on V1-V4 leads.

Figure 2. Coronaric spasm after ioversol administration in patient N 9

- A) Baseline angiography of right coronary artery (RCA) shows culprit lesion on middle segment.
- B) Direct coronary stent implantation on mid RCA.
- C) Angiographic evidence of diffuse coronary spasm involving the proximal RCA, distal RCA, posterior descending artery and postero-lateral artery (white narrows).
- D) Angiographic control of RCA after intracoronary epinephrine injection.

REFERENCES

1. Kounis NG. Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management. *Clin Chem Lab Med*. 2016;54(10):1545-59.
2. Kounis NG, Koniari I, Velissaris D, Tzani G, Hahalis G. Kounis Syndrome—not a Single-organ Arterial Disorder but a Multisystem and Multidisciplinary Disease. *Balkan Med J*. 2019;36(4):212-21.
3. Mueller UR. Cardiovascular disease and anaphylaxis. *Curr Opin Allergy Clin Immunol*. 2007;7(4):337-41.
4. Triggiani M, Patella V, Staiano RI, Granata F, Marone G. Allergy and the cardiovascular system. *Clin Exp Immunol*. 2008;153(Suppl 1):7-11.
5. Simons FE, Arduzzo LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. *World Allergy Organ J*. 2011;4(2):13-37.
6. Kounis NG, Koniari I. Anaphylaxis affects primarily the heart and coronary arteries: Implications of Kounis syndrome. *Asia Pac Allergy*. 2019;9(2):e13.
7. Goto M, Matsuzaki M, Fuchinoue A, Urabe N, Kawagoe N, Takemoto I, et al. Chronic atherosclerotic mesenteric ischemia that started to develop symptoms just after anaphylaxis. *Case Rep Gastroenterol*. 2012;6(2):300-8.
8. González-de-Olano D, Alvarez-Twose I, Matito A, Sánchez-Muñoz L, Kounis NG, Escribano L. Mast cell activation disorders presenting with cerebral vasospasm-related symptoms: a "Kounis-like" syndrome? *Int J Cardiol*. 2011;150(2):210-1.
9. Anastogiannis H, Litsardopoulos P, Anastopoulou GG, Petsas A, Tsigkas G, Kounis NG, et al. Irreversible diffuse hypoxic-ischemic encephalopathy, secondary to type I Kounis syndrome. *Int J Neurosci*. 2020;130(7):746-8.

10. Peláez-Pérez JM, Sánchez Casado M, Álvarez-Twose I, Kounis NG. Amoxicillin-clavulanic acid-induced type II Kounis syndrome during general anaesthesia complicated with hypoxic-ischaemic encephalopathy. *Rev Esp Anesthesiol Reanim* 2021;68(3):161-4.
11. Fassio F, Losappio L, Antolin-Amerigo D, Peveri S, Pala G, Preziosi D, et al. Kounis syndrome: A concise review with focus on management. *Eur J Intern Med.* 2016;30:7-10.
12. Li J, Zheng J, Zhou Y, Liu X, Peng W. Acute coronary syndrome secondary to allergic coronary vasospasm (Kounis Syndrome): a case series, follow-up and literature review. *BMC Cardiovasc Disord.* 2018;18(1):42.
13. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol.* 2006;117(2):391-7.
14. Ring J, Laubenthal H, Messmer K. Incidence and classification of adverse reactions to plasma substitutes. *Klin Wochenschr.* 1982;60(17):997-1002.
15. Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. *Allergy.* 2005;60(11):1339-49.
16. Golden DB, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update 2011. *J Allergy Clin Immunol.* 2011;127(4):852-4.e1-23.
17. Bilò MB, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, et al. Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice. *J Investig Allergol Clin Immunol.* 2019;29(3):180-205.
18. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. *Allergy.* 2002;57(1):45-51.
19. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. *Allergy.* 2003;58(10):961-72.

20. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, Bonadonna P, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. *Allergy*. 2009;64(2):234-41.
21. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy*. 2013;68(6):702-12.
22. Platzgummer S, Bizzaro N, Bilò MB, Pravettoni V, Cecchi L, Sargentini V, et al. Recommendations for the Use of Tryptase in the Diagnosis of Anaphylaxis and Clonal Mastcell Disorders. *Eur Ann Allergy Clin Immunol*. 2020;52(2):51-61.
23. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. *J Allergy Clin Immunol*. 2011;127(Suppl 3):S67-73.
24. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. *Allergy*. 2015;70(11):1393-405.
25. Tummala K, Maniyal VK, Chandrashekar R, Mathew N, Ganeshwala G. Cardiac anaphylaxis: a case of acute ST-segment elevation myocardial infarction after IM epinephrine for anaphylactic shock. *Am J Emerg Med*. 2013;31(7):1157.e1-3.
26. Shrestha B, Kafle P, Thapa S, Dahal S, Gayam V, Dufresne A. Intramuscular Epinephrine-Induced Transient ST-Elevation Myocardial Infarction. *J Investig Med High Impact Case Rep*. 2018;6:2324709618785651.
27. Renda F, Marotta E, Landoni G, Belletti A, Cuconato V, Pani L. Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases. *Int J Cardiol*. 2016;224:406-11.
28. Raschi E, Fertonani Affini L, Antonazzo IC, Diemberger I, Poluzzi E, De Ponti F. Drug-induced Kounis syndrome: A matter of pharmacovigilance. *Int J Cardiol*. 2019;274:381.
29. Ridella M, Bagdure S, Nugent K, Cevik C. Kounis syndrome following beta-lactam antibiotic use: review of literature. *Inflamm Allergy Drug Targets*. 2009;8(1):11-6.

30. Caragnano V, Distaso S, Scicchitano P, Chieppa DRR, Liotino M, Scialpi A, et al. Cardiac arrest in type II Kounis syndrome after oral intake of amoxicilline. *Am J Cardiovasc Dis.* 2020;10(3):195-200.
31. Hamilos MI, Kochiadakis GE, Skolidis EI, Igoumenidis NE, Zaharaki A, Vardas PE. Acute myocardial infarction in a patient with normal coronary arteries after an allergic reaction. *Hellenic J Cardiol.* 2005;46(1):79-82.
32. Wang CC, Chang SH, Chen CC, Huang HL, Hsieh IC. Severe coronary artery spasm with anaphylactoid shock caused by contrast medium--case reports. *Angiology.* 2006;57(2):225-9.
33. Del Furia F, Matucci A, Santoro GM. Anaphylaxis-induced acute ST-segment elevation myocardial ischemia treated with primary percutaneous coronary intervention: report of two cases. *J Invasive Cardiol.* 2008;20(3):E73-6.
34. Dauvergne C, Araya M, Abufhele A. Coronary spasm secondary to an allergic reaction or Kounis syndrome: report of one case. *Rev Med Chil.* 2009;137(6):811-4.
35. Kogias JS, Papadakis EX, Tsatiris CG, Hahalis G, Kounis GN, Mazarakis A, et al. Kounis syndrome: a manifestation of drug-eluting stent thrombosis associated with allergic reaction to contrast material. *Int J Cardiol.* 2010;139(2):206-9.
36. Park JM, Cho J, Chung SP, Kim MJ. Kounis syndrome captured by coronary angiography computed tomography. *Am J Emerg Med.* 2010;28(5):640.e5-8.
37. Kocabay G, Karabay CY, Kounis NG. Myocardial infarction secondary to contrast agent. Contrast effect or type II Kounis syndrome? *Am J Emerg Med.* 2012;30(1):255.e1-2.
38. Yanagawa Y, Tajima M, Ohara K, Aihara K, Matsuda S, Iba T. A case of cardiac arrest with ST elevation induced by contrast medium. *Am J Emerg Med.* 2012;30(9):2083.e3-4.
39. Xu M, Wu XS, Jiang TY, He JQ. Kounis syndrome: allergic acute coronary syndrome. *Chin Med J.* 2013;126(13):2591-2.

40. Bhaskaran A, Deshmukh T, Sivagangabalan G. Intraprocedure Type II Kounis Syndrome Secondary to Radioiodine Contrast During Coronary Angiography. *Can J Cardiol.* 2018;34(12):1688.e1-1688.e3.
41. Tripolino C, Tassone EJ, Morabito G, Grillo P, Missiroli B. Acute coronary stent thrombosis: A case of type 3 Kounis syndrome. *J Cardiol Cases.* 2018;19(1):33-35.
42. Shibuya K, Kasama S, Funada R, Katoh H, Tsushima Y. Kounis syndrome induced by contrast media: A case report and review of literature. *Eur J Radiol Open.* 2019;6:91-6.
43. Chien DS, Tsai AP, Lin PC, Yiang GT, Wu MY. Contrast Media Induced Kounis Syndrome: A Case Report. *Diagnostics (Basel).* 2019;9(4):154.
44. Dorniak K, Gałaska R, Fijałkowski M, Pieńkowska J, Łopaciński T, Węsierska M. Severe left ventricular outflow tract obstruction associated with Kounis syndrome following iodinated contrast administration. *Pol Arch Intern Med.* 2019;129(12):924-6.
45. Maadarani O, Bitar Z, Shoeb S, Alsaddah J. From Wellens To Kounis Syndrome: An Unlucky Patient. *Eur J Case Rep Intern Med.* 2020;7(9):001689.
46. Kogias JS, Sideris SK, Anifadis SK. Kounis syndrome associated with hypersensitivity to hymenoptera stings. *Int J Cardiol.* 2007;114(2):252-5.
47. Valla M, Moulin F, Angioi M, Groben L, Sadoul N, Aliot E. Myocardial infarction in a 45-year-old man following an anaphylactic reaction to a wasp sting. *Int J Cardiol.* 2011;148(3):e63-5.
48. Rekik S, Andrieu S, Aboukhoudir F, Barnay P, Quaino G, Pansieri M, et al. ST elevation myocardial infarction with no structural lesions after a wasp sting. *J Emerg Med.* 2012;42(4):e73-5.
49. Ridolo E, Olivieri E, Montagni M, Rolli A, Senna GE. Type I variant of Kounis syndrome secondary to wasp sting. *Ann Allergy Asthma Immunol.* 2012;109(1):79-81.
50. Ralapanawa DM, Kularatne SA. A case of Kounis syndrome after a hornet sting and literature review. *BMC Res Notes.* 2014;7:867.
51. Scherbak D, Lazkani M, Sparacino N, Loli A. Kounis syndrome: a stinging case of ST-elevation myocardial infarction. *Heart Lung Circ.* 2015;24(4):e48-50.

52. Anandan PK, Hanumanthappa NB, Bhatt P, Cholenahally MN. Allergic angina following wasp sting: Kounis syndrome. *Oxf Med Case Reports*. 2015;2015(6):306-8.
53. Cholevas NV, Rallidis LS, Staurothanasopoulou A, Pagaki E, Platogiannis D. Kounis syndrome type I in a victim of cardiopulmonary arrest after hymenoptera sting. *J Cardiol Cases*. 2017;15(4):141-4.
54. Cross B, Choudhury TR, Hindle M, Galasko G. Wasp sting induced STEMI with complete coronary artery occlusion: a case of Kounis syndrome. *BMJ Case Rep*. 2017;2017:bcr2017221256.
55. López-Abad R, Rodríguez F, García-Abujeta JL, Martín-Gil D, Jerez J. Myocardial ischemia due to severe amoxicillin allergy. *J Investig Allergol Clin Immunol*. 2004;14(2):162-4.
56. Moreno-Ancillo A, Domínguez-Noche C, Gil-Adrados AC, Cosmes Martn PM. Acute coronary syndrome due to amoxicillin allergy. *Allergy*. 2004;59(4):466-7.
57. Gikas A, Lazaros G, Kontou-Fili K. Acute ST-segment elevation myocardial infarction after amoxycillin-induced anaphylactic shock in a young adult with normal coronary arteries: a case report. *BMC Cardiovasc Disord*. 2005;5(1):6.
58. Del Furia F, Querceto L, Testi S, Santoro GM. Acute ST-segment elevation myocardial infarction complicating amoxycillin-induced anaphylaxis: a case report. *Int J Cardiol*. 2007;117(1):e37-9.
59. Yurtdaş M, Aydin MK. A case of coronary spasm with resultant acute myocardial infarction: likely the result of an allergic reaction. *Intern Med*. 2012;51(16):2161-4.
60. Sánchez VO, Roca LC, Moreno Adel P. Intraoperative "Kounis syndrome" that improved electrocardiography changes and hemodynamic situation after administering nitroglycerine. *Braz J Anesthesiol*. 2014;64(4):281-5.
61. Mota I, Gaspar Â, Morais-Almeida M. Perioperative Anaphylaxis Including Kounis Syndrome due to Selective Cefazolin Allergy. *Int Arch Allergy Immunol*. 2018;177(3):269-73.
62. Sequeira T, Gaspar Â, Mota I, Correia M, Chambel M, Morais-Almeida M. Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin. *J Investig Allergol Clin Immunol*. 2018;28(4):257-8.

63. Adachi H, Ihara M, Nojima Y, Kurimoto T, Nanto S. Kounis syndrome caused by anaphylaxis without skin manifestations after cefazolin administration. *J Allergy Clin Immunol Pract.* 2019;7(1):317-9.
64. Sato M, Arai T. A case of Kounis syndrome presenting as coronary artery spasm associated with cefazolin-induced anaphylaxis during general anesthesia. *JA Clin Rep.* 2019;5(1):49.
65. Absmaier M, Biedermann T, Brockow K. Allergic myocardial infarction (Kounis syndrome) after cefuroxime with side-chain cross-reactivity. *J Allergy Clin Immunol Pract.* 2018;6(5):1781-1783.e1.
66. González-de-Olano D, Gandolfo-Cano M, Mohedano-Vicente E, González-Mancebo E, Matito A, Kounis NG, et al. Kounis syndrome following the performance of skin test to amoxicillin. *Int J Cardiol.* 2014;174(3):856-7.
67. Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. *Allergy.* 2020;75(6):1300-15.

1 **Table I.** Demographics, clinical features, cardiological and allergological outcomes of the 4
 2 subjects who had reacted to hymenoptera stings
 3

	Patient 1	Patient 2	Patient 3	Patient 4
Gender/Age	M/67	M/60	M/40	M/71
Atopy	No	Yes (HDM AR)	No	No
Cardiovascular risk factors	Yes (dyslipidemia, smoke, blood hypertension)	Yes (dyslipidemia, blood hypertension)	Yes (dyslipidemia, smoke)	Yes (type-2 diabetes, blood hypertension)
Allergic triggers	Polistes dominula venom	Vespula species venom	Vespula species venom	Vespula species venom
Symptoms	Eyelid angioedema, throat tightness, dyspnea, desaturation, hypotension, loss of consciousness	Urticaria, dyspnea, severe epigastralgia	Generalized itching, throat tightness, chest pain	Itching of palms, erythema, face edema, throat tightness, dyspnea, loss of consciousness, cardiac arrest
Severity grading	Grade III	Grade II	Grade II	Grade IV
ECG	↓ ST	Anterior STEMI	Transient ↓ ST	PEA
Troponin-I^a	2.4 ng/mL	4.38 ng/mL	np	4.55 ng/mL
Tryptase, AS^b	np	13 mcg/L	np	np
Basal tryptase^c	11.2 mcg/L	4 mcg/L	4 mcg/L	4.5 mcg/L
Coronary angiography	Three-vessel disease	Mono-vessel disease	Normal	np
Echocardiography	np	np	np	Negative
Kounis type	II	II	I	I
Venom specific IgE assay	PoD: 0.51 kUA/L; HB and YJ: < 0.1 kUA/L	YJ: 2 kUA/L; PoD: 0.4 kUA/L; HB: < 0.1 kUA/L	YJ: 23 kUA/L; PoD: 3.9 kUA/L; HB: < 0.1 kUA/L	YJ: 4 kUA/L; PoD: 1.4 kUA/L; HB: < 0.1 kUA/L
Skin testing	IDT positive to PoD at 1 µg/mL. STs negative to HB and YJ	IDT positive to YJ at 0.1 µg/mL. STs negative to HB and PoD	IDT positive to YJ at 0.1 µg/mL; STs negative to HB and PoD	IDT positive to YJ at 0.01 µg/mL, PoD at 0.01 µg/mL, and HB at 1 µg/mL.
VIT	Yes (for PoD)	Yes (for YJ)	Yes (for YJ)	Yes (for YJ)

4
 5 AS, acute setting; ECG, electrocardiogram; HB, honey bee; HDM AR, house dust mite allergic rhinitis;
 6 IDT, intradermal test; M, male; np, not performed; PEA, pulseless electrical activity; PoD, Polistes
 7 dominula; STs, skin tests; STEMI, ST-elevated myocardial infarction; VIT, venom immunotherapy; YJ,
 8 yellow jacket.

9
 10 ^aNormal values: < 0.04 ng/mL

11 ^bNormal values: < 2 + (1.2 x basal tryptase level) mcg/L

12 ^cNormal values: < 11.4 mcg/L

1 **Table II.** Demographics, clinical features, cardiological and allergological outcomes of the 5
 2 subjects who had reacted to drugs
 3


	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9
Gender/Age	F/49	F/60	F/78	F/54	F/65
Atopy	No	Yes (drug allergy)	No	No	No
Cardiovascular risk factors	Yes (hypertension)	Yes (smoke)	No	Yes (smoke)	Yes (smoke)
Allergic triggers	Unknow ICM	Oral AX/clav	Intravenous CT	Oral AX/clav	IOV
Symptoms	Throat tightness, dyspnea, loss of consciousness, cardiac arrest	Vomiting, dyspnea, bronchospasm, hypotension, loss of consciousness	Erythema, dyspnea, urinary incontinence, cardiac arrest	Erythema, dyspnea, cyanosis, loss of consciousness, cardiac arrest	Throat tightness, hypotension, coronary spasm, peri-cardiac arrest
Severity grading	Grade IV	Grade III	Grade IV	Grade IV	Grade IV
ECG	PEA	Transient ↑ ST	PEA	PEA	STEMI*
Troponin-I^a	1.13 ng/mL	1.55 ng/mL	3.75 ng/mL	0.04 ng/mL	180 ng/L*
Tryptase^b, AS	np	np	92.4 mcg/l	np	np
Basal tryptase^c	np	7.8 mcg/L	5.7 mcg/L	4.6 mcg/L	8.1 mcg/L
Coronary angiography	np	np	np	np	Mono-vessel disease
Echocardiography	Negative	Negative (also ergometric testing)	Inferobasal hypokinesia	Negative	np
Kounis type	Type I	Type I	Type I	Type I	Type II
In vitro testing	np	Specific IgE assay: AX: 0.31 kUA/L; PG, PV, AM, and CE: < 0.10 kUA/L	Specific IgE assay: PG, PV, AM, AX, and CE: < 0.10 kUA/L	Specific IgE assay: PG: 0.25 kUA/L PV: 0.47 kUA/L AX: 0.14 kUA/L CE: 0.15 kUA/L	BAT: Positive to IOV, IOM, IOB, IOP; negative to IOH, IOPR.
Skin testing	np	SPT positive to AX and AM at 20 mg/mL; IDT positive to CFT, CFR, CFZ and CFX at 2 mg/mL. STs negative to CTZ at 2 mg/ml and meropenem at 1 mg/ml	np	np	STs negative to IOPR

4
 5 ACLS, advanced cardiac life support; AM, ampicillin; AX, amoxicillin; AS, acute setting; clav, clavulanic
 6 acid; CE, cefaclor; CFT, ceftriaxone; CFR, cefuroxime; CFZ, cefazolina; CFX, cefotaxime; CTZ,
 7 ceftazidime; ECG, electrocardiogram; F, female; ICM: iodinated contrast media; IDT, intradermal test; IOB,
 8 iobitridol; IOH, iohexol; IOM, iomeprol; IOP, iopamidol; IOPR, iopromide; IOV, ioversol; np, not
 9 performed; PEA, pulseless electrical activity; PG, penicilloyl G; PV, penicilloyl V; SPT, skin prick test; STs,
 10 skin tests; STEMI, ST-elevated myocardial infarction. *STEMI, ST-elevated myocardial infarction was just
 11 present at admission.

12
 13 ^aNormal values: < 0.04 ng/mL and < 37 ng/L


14 ^bNormal values: < 2 + (1.2 x basal tryptase level) µg/L

15 ^cNormal values: < 11.4 µg/L




Manuscript accepted


A




B



C



D



Manuscript accepted for publication